Sunesis Pharmaceuticals Inc., of South San Francisco, said the first patients have been treated in the investigator-sponsored VITAL (Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia) phase II study of vosaroxin in combination with cytarabine in patients with previously untreated acute myeloid leukemia (AML).